Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT04609176 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Camrelizumab plus Apatinib and SOX
DRUG: Camrelizumab plus Apatinib

Sponsor

Peking University

Collaborators

[object Object]